DBV Technologies Sets Stage For 'Swift' Success As Breakthrough Peanut Patch Nears FDA Submission

DBV Technologies SA (NASDAQ: DBVT) is on track to submit its biologics license application (BLA) for the VIASKIN peanut patch for children to the US FDA in the first half of this year, with potential for priority review due to the unmet need for pediatric food allergies. The company reported a net loss of approximately $147 million for fiscal 2025, equating to $1.05 per share, while maintaining a cash position of around $284 million, providing operational runway into the second quarter of 2027. Analyst Yatin Suneja has a Buy rating with a price target of $51, anticipating swift uptake of the product upon approval. As of the latest report, DBV Technologies shares were down 0.69% at $20.07.